271 related articles for article (PubMed ID: 18065961)
21. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
[TBL] [Abstract][Full Text] [Related]
22. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
[TBL] [Abstract][Full Text] [Related]
23. Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.
Bonaccorsi L; Nesi G; Nuti F; Paglierani M; Krausz C; Masieri L; Serni S; Proietti-Pannunzi L; Fang Y; Jhanwar SC; Orlando C; Carini M; Forti G; Baldi E; Luzzatto L
J Endocrinol Invest; 2009 Jul; 32(7):590-6. PubMed ID: 19494719
[TBL] [Abstract][Full Text] [Related]
24. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
25. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.
Park K; Dalton JT; Narayanan R; Barbieri CE; Hancock ML; Bostwick DG; Steiner MS; Rubin MA
J Clin Oncol; 2014 Jan; 32(3):206-11. PubMed ID: 24297949
[TBL] [Abstract][Full Text] [Related]
26. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
[TBL] [Abstract][Full Text] [Related]
27. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
[TBL] [Abstract][Full Text] [Related]
28. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.
Lapointe J; Kim YH; Miller MA; Li C; Kaygusuz G; van de Rijn M; Huntsman DG; Brooks JD; Pollack JR
Mod Pathol; 2007 Apr; 20(4):467-73. PubMed ID: 17334351
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.
Green WM; Hicks JL; De Marzo A; Illei PP; Epstein JI
Hum Pathol; 2013 Sep; 44(9):1895-901. PubMed ID: 23664537
[TBL] [Abstract][Full Text] [Related]
30. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.
Sun C; Dobi A; Mohamed A; Li H; Thangapazham RL; Furusato B; Shaheduzzaman S; Tan SH; Vaidyanathan G; Whitman E; Hawksworth DJ; Chen Y; Nau M; Patel V; Vahey M; Gutkind JS; Sreenath T; Petrovics G; Sesterhenn IA; McLeod DG; Srivastava S
Oncogene; 2008 Sep; 27(40):5348-53. PubMed ID: 18542058
[TBL] [Abstract][Full Text] [Related]
31. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
[TBL] [Abstract][Full Text] [Related]
32. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
[TBL] [Abstract][Full Text] [Related]
33. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
[TBL] [Abstract][Full Text] [Related]
34. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
[TBL] [Abstract][Full Text] [Related]
36. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG.
Warrick JI; Tomlins SA; Carskadon SL; Young AM; Siddiqui J; Wei JT; Chinnaiyan AM; Kunju LP; Palanisamy N
Mod Pathol; 2014 Apr; 27(4):609-20. PubMed ID: 24072184
[TBL] [Abstract][Full Text] [Related]
38. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.
Guo CC; Wang Y; Xiao L; Troncoso P; Czerniak BA
Hum Pathol; 2012 May; 43(5):644-9. PubMed ID: 21937078
[TBL] [Abstract][Full Text] [Related]
39. Retention of Interstitial Genes between
Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
[No Abstract] [Full Text] [Related]
40. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
